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Abstract 
Objective: Asthma is caused by a complex interaction between multiple genes and envi-
ronmental factors. Herein we aimed to investigate whether signal transducer and activator 
of transcription (STAT2), toll-like receptors 4 (TLRs4) and CD40-related polymorphisms 
are associated with asthma susceptibility.   
Design:  Children were divided: (1) asthma (n=117); (2) normal controls (n=60). The 
polymorphisms of STAT2, TLR4 and CD40 polymorphism were analyzed by PCR-RFLP 
genotyping. Genotypes, allelic frequencies and association of haplotypes in both groups were 
compared.  
Results: STAT2*C related genotypes, but not TLR4 and CD40 polymorphism, are associ-
ated with higher susceptibility for asthma. Distributions of STAT2*CC/CG/GG and C/G al-
lele in both groups are: (1) 0/11.1/88.9 % and 5.6/94.4%; (2) 0/1.7/98.3% and 0.8/99.2% 
(p<0.05). Proportions of TLR4*rs10983755 AA/AG/GG and rs1927914 CC/CT/TT homo-
zygote are: (1) 35.1/8.5/56.4% and 9.4/56.4/34.2%; (2) 35/8.3/56.7% and 16.7/48.3/35% 
(non-difference). Proportions of CD40*rs1883832 CC/CT/TT, rs3765459 AA/AG/GG, and 
rs4810485 TT/GT/GG are: (1) 29.9/53/17.1%, 6.8/47.9/45.3 and 18.8/62.4/18.8%; (2) 
36.7/41.7/21.6%, 1.6/46.7/ 51.7 and 15/51.7/33.3% (non-difference). Haplotype analyses for 
TLR4 and CD40 genes revealed their non-association and non-additional effect upon asthma 
susceptibilities.  
Conclusion: STAT2*C related genotypes and alleles are associated with asthma suscepti-
bilities and pathogenesis. There were non-association and non-additional effects of 
TLR4/CD40 gene polymorphisms and haplotypes upon asthma risk. 
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Introduction 
Asthma, one major respiratory consequence, 
appeared around 6-9% prevalence in general popula-
tion [1]. The incidence of asthma appeared the in-
creased trend during past decade. Asthma is caused 
by a complex interaction between multiple candidate 
genes and environmental factors. However, the re-
lated molecular basis for this upper airway disorder 
remains unclear. The raised incidence of asthma has Int. J. Biol. Sci. 2009, 5 
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been attributed to increased environment contamina-
tion, overusage of antibiotics as well as constitutional 
and genetic factors. However, the mechanistic roles of 
the disease-associated SNPs have yet to be elucidated 
especially in the context of the pathophysiology of 
asthma. Furthermore, the related factor for predicting 
asthma susceptibilities remains obscure.   
Numerous cytokines play an important role in 
allergic immune disorders, such as asthma. Proin-
flammatory cytokines could contribute to this in-
flammatory process for asthma [2]. These cytokines 
regulate diverse biological functions by binding to 
receptors at the cell surface to activate complex signal 
transduction pathways, including the signal trans-
ducer and activator of transcription (STAT) signaling 
pathways. The STAT pathway mediates the signals of 
a wide range of cytokines, growth factors and hor-
mones. Aberrant activation of STAT pathway may 
predispose to cell dysfunction or dysregulation. Sig-
nal transducer and activator of transcription (STAT) 
has been demonstrated to be associated with asthma 
susceptibilities [3]. Some STAT gene variation 
(C39134A) might be associated with IgE regulation 
and atopy [4]. . 
 Infectious diseases have a major impact on both 
the development and severity of asthma. Innate im-
munity status and related genetic variations have 
been reported to be associated with inflammatory 
disorders such as asthma. Toll-like receptors (TLRs) 
are involved in immune responses towards various 
micro-organisms. TLRs are innate immune sensors of 
microbial cell wall products that initiate early host 
responses [5]. TLRs play a pivotal role in the induc-
tion of first-line defense mechanisms of the immune 
system and trigger adaptive immune responses to 
microbial pathogens.   
The CD40 protein plays important roles in 
cell-mediated and humoral immune responses [6]. 
CD40 protein is expressed in a variety of cell types. 
CD40 ligation causes cells to produce inflammatory 
cytokines and cellular adhesion molecules. CD40 
gene polymorphisms exert a genetic effect on IgE 
production in patients with asthma through transla-
tional regulation of CD40 expression on B cells [6]. 
Asthma is characterized by airway smooth muscle 
hyperplasia, inflammatory cell infiltration, and in-
creased expression of cytokines. These cytokines have 
the potential to alter the expression of surface recep-
tors such as CD40 ligand on the airway smooth mus-
cle cell [7].   
  Reviewing MEDLINE database, few investiga-
tor demonstrated the correlation of STAT2, TLR4 and 
CD40 gene polymorphisms with asthma. Further-
more, literatures about the genetic associations of 
STAT2, TLR4, and CD40 upon asthma are inconsis-
tent. In this survey, our genetic targets were all im-
port roles amongst the complex pathogenesis of 
asthma, including the cytokine signals (STAT), viral 
defense (TLR) and immune response (CD40). We 
aimed to evaluate whether STAT2, TLR4 and CD40 
gene polymorphisms are attractive markers for pre-
dicting the susceptibility of asthma. We also per-
formed linkage and association analyses in these can-
didate regions. To the best of our knowledge, this is 
the first survey in this field.   
Patient and methods 
All individuals were divided into two groups: 
(1) asthma (classification of asthma) (n=117); (2) nor-
mal controls (n=60). Taiwanese children with diagno-
sis of asthma were included. Asthmas was diagnosed 
as standard criteria, as previous describes [8]. The 
controls were consisted with health children. All in-
dividuals accepted the peripheral blood sampling for 
genotype analyses. The clinical data about the FEV1 
or FEV1/FVC for the asthma individuals were also 
collected. The experiment was approved by Ethical 
Committee and Institutional Review Board of China 
Medical University Hospital.   
The genomic DNA was prepared from periph-
eral blood leukocytes by use of a genomic DNA isola-
tion kit (Blossom, Taipei, Taiwan). A total of 50 ng 
genomic DNA was mixed with 20 pmol of each po-
lymerase chain reaction (PCR) primer in a total vol-
ume of 25 μl containing 10 mM Tris-HCL pH 8.3, 50 
mM potassium chloride, 2.0 mM magnesium chlo-
ride, 0.2 mM each deoxyribonucleotide triphosphate, 
and 1 U DNA polymerase (Amplitag; Perkin-Elmer, 
Foster City, CA, USA). The PCR primer sequences 
and condition of each primer were listed in Table 1. 
The PCR amplification was performed in a pro-
grammable thermal cycler GenAmp PCR system 2400 
(Perkin Elmer Applied Biosystems, Foster City, CA, 
USA).  
After PCR amplification, the STAT2, TLR4 and 
CD40 gene polymorphisms were analyzed by restric-
tion digestion with restriction enzymes (New Eng-
l a n d  B i o l a b s ,  I n c ,  B e v e r l y ,  M A ) .  T h e  r e s t r i c t i o n  e n -
zymes used for each DNA polymorphisms were 
listed in Table 1. Electrophoresis of the PCR product 
was performed on a 3 % agarose gel and stained with 
ethidium bromide to visualize the amplified DNA 
bands. The individual PCR conditions, following 
electrophoresis and base pairs for their wild and SNP 
types were listed in Table 1.   
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Table 1. The primer sequences, PCR conditions and restriction enzymes used in detecting STAT2, TLR4, and CD40 
polymorphisms.  
Gene (rs number)  Primer pairs  Alleles Restriction 
Enzyme 
Genotype: length of DNA 
fragments (bp) 
Anneling Temperature 
(℃) 
STAT2 
(rs2066807)-F 
5'-CTCGGAAGGTGGCTATTGTC-3' C/G  Tth111I  CC:366  GG:244+122  TOUCH  DOWN 
(51-60) 
STAT2 
(rs2066807)-R 
5'-AAAGGAGAGGCTGTGGGAAT-3'          
            
TLR4(rs10983755)-F 5'-TCCACCTTGGATGACTATGT-3'  A/G  HpyCH4IV  AA:304  GG:243+61  58 
TLR4(rs10983755)-R 5'-TATGCATGCTAAGTCCTAGA-3'           
            
TLR4(rs1927914)-F  5'- ACGTCTAGTCTAGAGCATCA -3'  C/T   NsiI  TT:270  CC:221+49  58 
TLR4(rs1927914)-R  5'- ATTGGAAGTGCTTGGAGGAT -3'           
            
CD40 (rs1883832)-F  5'-TACACAGCAAGATGCGTCC CT-3'  C/T  NcoI   TT:291  CC:229+62  58 
CD40 (rs1883832)-R  5'-AACAACTCACAGCGGTCAGCAA-3'          
            
CD40 (rs3765459)-F  5'-ATGCTCCTTCCATCCAGA -3'  A/G  HpyCH4III GG:421  AA:263+158  58 
CD40 (rs3765459)-R  5'-TCGTCGGGAAAATTGATCTC CT -3'          
            
CD40 (rs4810485)-F  5'-TTAGGAGACCAGAGTTCT-3'  G/T  MspI  TT:259+102 GG:148+111+102  58 
CD40 (rs4810485)-R  5'-AAAGCTGTGGGACCAAAGCA-3'                          
*F and R indicate forward and reverse primers 
 
 
Genotypes and allelic frequencies for STAT2, 
TLR4 and CD40 gene polymorphisms in both groups 
were compared. Correlations of these gene polymor-
phisms and asthma were evaluated. Allelic frequen-
cies are expressed as a percentage of the total number 
of alleles. The associations of different genotypes 
with FEV1 or FEV1/FVC for the asthma individuals 
were also estimated. The SAS package (Version 8.1, 
SAS Institute Inc., Cary, North Carolina, USA) with χ2 
and Fisher’s extract tests were utilized for statistical 
analyses. A p-value of <0.05 was considered statisti-
cally significant.   
 
Results 
 The average age of onset and recruitment in the 
asthma group were 7.2±2.4 and 9.6±3.5 years, respec-
tively. Genotype proportions of different gene poly-
morphisms of STAT2 in both groups were signifi-
cantly different (Table 2, 3). Distributions of STAT2*C 
homozygote/CG heterozygote/G homozygote and 
C/G allele in both groups are: (1) 0/11.1/88.9 % and 
5.6/94.4%; (2) 0/1.7/98.3% and 0.8/99.2% (p<0.05, 
Table 2). There is no individuals with STAT2*C ho-
mozygote.  
Table 2. Genotypes and allelic frequencies for STAT2 gene 
polymorphism in individuals with and without asthma 
STAT2 
rs2066807
Asthma 
(n=117) 
Control 
(n=60) 
p*  OR  95% CI for 
OR 
Genotype         
CC  0  0  0.03   7.38   0.94 57.80 
CG  13 (11.1)  1 (1.7)       
GG  104 (88.9)  59 (98.3)       
        
Allele          
C  13 (5.6)  1 (0.8)  0.03   7.00   0.90 54.17 
G  221 (94.4)  119 (99.2)                
* Fisher’s extract tests 
 
 
STAT2*C related genotypes and allele are asso-
ciated with higher susceptibility for asthma. In con-
trast, TLR4 polymorphisms are not associated with 
asthma development. Proportions of TLR4*rs 
10983755 A homozygote/AG heterozygote/G ho-
mozygote in both groups are: (1) 35.1/8.5/56.4%; (2) 
35/8.3/56.7% (non-difference, Table 3). Proportions 
of TLR4*rs1927914 C homozygote/CT heterozy-
gote/TT homozygote in both groups are: (1) 
9.4/56.4/34.2%; (2) 16.7/48.3/35% (non-difference, 
Table 3).   Int. J. Biol. Sci. 2009, 5 
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Table 3. Genotypes and allelic frequencies for TLR4 gene 
polymorphism in individuals with and without asthma.  
 Asthma 
(n=117) 
Control 
(n=60) 
p*  OR  95% CI for 
OR 
TLR4 
rs10983755 
        
Genotype          
AA  41 (35.1)  21 (35)  1.00   1.01   0.30 3.32 
AG  10 (8.5)  5 (8.3)    1.03   0.33 3.26 
GG  66 (56.4)  34 (56.7)       
          
Allele         
A  92 (39.3)  47 (39.2)  0.98   1.01   0.64 1.58 
G  142 (60.7)  73 (60.8)       
TLR4 
rs1927914 
        
Genotype          
CC  11 (9.4)  10 (16.7)  0.32   0.58   0.22 1.51 
CT  66 (56.4)  29 (48.3)    1.19   0.60 2.37 
TT  40 (34.2)  21 (35)       
          
Allele         
C  88 (37.6)  49 (40.8)  0.56   0.87   0.56 1.37 
T  146 (62.4)  71 (59.2)       
*χ2 test 
 
 
  Furthermore, three genetic variations for CD40 
are not associated with asthma susceptibilities. Pro-
portions of CD40*rs1883832 C homozygote/CT het-
erozygote/T homozygote in both groups are: (1) 
29.9/53/17.1%; (2) 36.7/41.7/21.6% (non-difference, 
Table 4). Proportions of CD40*rs3765459 A homozy-
gote/AG heterozygote/G homozygote in both 
groups are: (1) 6.8/47.9/45.3; (2) 1.6/46.7/ 51.7% 
(non-difference, Table 4). Proportions of 
CD40*rs4810485 TT homozygote/GT heterozy-
gote/GG homozygote in both groups are: (1) 
18.8/62.4/18.8%; (2) 15/51.7/33.3% (non-difference, 
Table 4). Concerning the association between the as-
sociation of different halotypes for TLR4 and CD40 
gene polymorphisms as well as their additional ef-
fects upon asthma risks, the statistical analyses re-
vealed their non-association and absence of addi-
tional effect upon the asthma susceptibilities (Table 5, 
6). Concerning the associations between STAT2 
genotype and lung functions, we also observed the 
non-association between different genetic variation 
and FEV1 or FEV1/FVC values for the asthma indi-
vidual (Table 7).   
 
Table 4. Genotypes and allelic frequencies for CD40 gene 
polymorphism in individuals with and without asthma 
 Asthma 
(n=117) 
Control 
(n=60) 
p*  OR  95% CI for 
OR 
CD40 
rs1883832 
        
Genotype          
CC  35 (29.9)  22 (36.7)  0.36   1.034   0.510 2.097
CT  62 (53)  25 (41.7)    1.612   0.697 3.729
TT  20 (17.1)  13 (21.6)       
          
Allele          
C  132 (56.4)  69 (57.5)  0.84   0.957   0.613 1.492
T  102 (43.6)  51 (42.5)       
CD40 
rs3765459 
        
Genotype          
AA  8 (6.8)  1 (1.6)  0.25   4.679   0.557 
39.289  
AG  56 (47.9)  28 (46.7)    1.170   0.620 
39.289 
GG  53 (45.3)  31 (51.7)       
          
Allele          
A  72 (30.8)  30 (25)  0.24   1.333   0.810 2.193
G  162 (69.2)  90 (75)       
CD40 
rs4810485 
        
Genotype          
TT  22 (18.8)  9 (15)  0.10   2.222   0.920 5.369
GT  73 (62.4)  31 (51.7)    2.141   1.024 4.474
GG  22 (18.8)  20 (33.3)       
          
Allele          
T  117 (50)  49 (40.8)  0.10   1.449   0.928 2.262 
G  117 (50)  71 (59.2)       
*χ2 test 
 
 
 
 
 
 
Table 5. Haplotype analysis for TLR4 gene polymorphisms 
Haplotype rs10983755 rs1927914 Asthma 
pa-
tients 
Control p Odds 
ratio(95% 
CI) 
Ht 1  G  T  0.462  0.442  0.721 1.08 
(0.70-1.69)
Ht 2  A  C  0.225  0.242  0.719 0.91 
(0.54-1.53)
Ht 3  A  T  0.162  0.167  0.904 0.96 
(0.53-1.74)
Ht 4  G  C  0.151  0.15  0.980 1.01 
(0.54-1.87)
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Table 6. Haplotype analyses for CD40 gene polymorphisms 
Haplotype  rs1883832  rs4810485  rs3765459  Asthma patients  Control  p  Odds ratio(95% CI) 
Ht 5  T  T  G  0.402  0.389  0.813   1.06 (0.67-1.66)  
Ht 6  C  G  A  0.263  0.225  0.435   1.23 (0.73-2.06)  
Ht 7  C  G  G  0.208  0.335  0.009   0.52 (0.32-0.85) 
Ht 8  C  T  G  0.048  0.025  0.297   1.97 (0.54-7.17) 
Ht 9  C  T  A  0.041  0.012  0.137   3.52 (0.60-20.58) 
Ht 10  T  G  G  0.032   0.013  0.284   2.51 (0.44-14.29) 
 
Table 7. Association between STAT2 genotypes with FEV1 
or FEV1/FVC. 
STAT2 
rs2066807 
Asthma FEV1  (%)  FEV1/FVC 
(%) 
p* 
CC 0  0  0  NS 
CG 13  (11.1) 70±12  68±13   
GG 104  (88.9)  73±15  72±18   
*: The differences were determined by univariated analysis of 
variances.  
 
Discussion 
Bronchial asthma is a chronic airway disorder 
characterized by reversible bronchial hy-
per-responsiveness and airway inflammation. 
Asthma is a multifactorial disease influenced by ge-
netic and environmental factors. While environ-
mental factors are critical for asthma development, 
genetic factors also play a major role in its clinical 
expressions [9]. Oxidative stress is a key component 
of inflammation. Inflammation is a key mechanism in 
asthma. Variation in genes encoding inflammatory 
responses might influence asthma risk through inter-
action with chronic inflammation and 
pro-inflammatory environmental risk factors, such as 
sedentary conditions, lifestyle, and air pollutions. 
However, the mechanism for asthma is complex. The 
precise physiological stimulus mediating asthma 
presentation remains obscure.   
  Growing evidences suggest that asthma is a 
multi-step process of genetic alterations. Some possi-
ble factors have been implicated with asthma, in-
cluding cytokines, signal ligants, and defense factors. 
Genetic surveys for asthma might provide insight 
into related pathophysiology and mechanisms. Dur-
ing past decades, several loci and genes have been 
found to be associated with the disorder [10]. Nu-
merous genetic factors might interfere with the in-
flammatory capacity of leukocytes, thus altering 
whole body allergy and asthma events. Some patients 
with different clinical phenotypes might display 
variable susceptibilities toward asthma.   
STAT is associated with endothelial expression, 
transcription and regulations of cytokines, including 
interleukin, nitric oxide synthesis, p21 and interferon 
[11]. STAT function has been implicated in the trans-
duction of signals for growth, reproduction, viral de-
fense, and immune regulation [12]. STAT cascade are 
required for cytokines, growth factors, G-proteins 
and hormones (growth hormone and prolactin) [13]. 
Expression of some cytokines could be regulated by 
STAT proteins [14]. Transcription factors of STAT 
family are required for cellular responses to multiple 
signaling molecules [15]. After ligand bind-
ing-induced activation, STAT proteins are phos-
phorylated and translocated to the nucleus [16]. Then 
STAT binds to nuclear DNA elements in the promot-
ers of specific genes, which further alter the tran-
scriptional activity of these loci.   
STAT gene is a positional candidate located on 
chromosome 2 [17]. STAT gene may be associated 
with predisposition to allergic diseases [18]. STAT 
gene represents one of the most promising candidate 
genes for asthma [19]. Numerous disorders were as-
sociated with STAT expressions, including asthma 
[3,20]. Leung et al. demonstrated the association be-
tween STAT6* C1570T genetic variation and lung 
function changes in asthma individuals [3]. Litonjua 
et al. indicated the STAT3 genetic polymorphism 
might participate in inflammatory pathways that 
have an impact on level of lung function [20]. Li et al. 
suggested that STAT-4 T90089C but not STAT-6 
G2964A polymorphisms might be the genetic factors 
for the risk of asthma in Chinese population [21]. 
STAT gene might be involved in the development of 
eosinophilia and changes in total IgE levels in asthma 
individuals [19,22].   
TLR, a key element in activating inflammatory 
cascade, plays a critical mediator of the immune re-
sponse to pathogens. TLRs are highly conserved 
trans-membrane proteins that play an important role 
in the detection and recognition of microbial patho-
gens. Alterations of TLR signaling molecules might 
be associated with clinical presentation and suscepti-
bility to infectious diseases such as asthma. TLRs play 
important roles in the signaling of many patho-
gen-related molecules and endogenous proteins asso-
ciated with immune activation [23]. TLR signaling 
could induce the production of inflammatory cyto-
kines and proteins in antigen presenting cells. Since Int. J. Biol. Sci. 2009, 5 
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leukocyte adhesion is a critical event in airway in-
flammation and asthma, it is logical to suspect TLR 
might be involved in asthma pathogenesis. TLR 
pathway plays an important role in mediating whole 
body inflammation, which has been implicated in the 
development of chronic disease.   
CD40 ligand is a transmembrane glycoprotein 
structurally related to tumour necrosis factor-alpha. 
CD40 ligation has been shown to promote anti-
gen-presenting functions of immune cells, which ex-
press CD40 receptor. Some disorders have been 
demonstrated to be associated with CD40, including 
Graves' disease (GD) [24], atherosclerosis [25], multi-
ple sclerosis [26]. CD40 gene polymorphism 
(C-1T)*C/C genotype has been reported to be associ-
ated with Graves' disease (GD) [24]. The interruption 
of CD40 signaling might produces a more fibrous and 
stable atherosclerotic lesion [25]. Carriers of T allele 
showed a trend for a lower stimulatory index com-
pared with individuals with C homozygote, which 
might further interfere with the illness course of mul-
tiple sclerosis [26]. The CD40 protein might influence 
the production and function of immunoglobulin E 
[6].  
  Single nucleotide polymorphism (SNP) results 
from a base substitution  mutation. Some cytokine 
polymorphisms have been reported to be protective 
or susceptible associated with asthma [27]. SNPs in 
protein-coding regions might result  in a missense 
mutation (synonymous), with a change of amino ac-
ids or a nonsense mutation (non-synonymous) occur-
ring in a termination codon. In addition, SNPs in 
promoter regions could result in reduced or increased 
gene expression, whereas SNPs in introns could result 
in defective splicing or a change in transcription rate 
if a regulatory element is mutated. SNPs occur on av-
erage every 1.9 kb in the genome where 1.42 million 
SNPs have been mapped with over 60,000 being rep-
resented within exons and untranslated regions [28]. 
In this study, we firstly observed some association 
existed between asthma susceptibility and STAT2 
genetic variations. It suggested that STAT gene might 
be susceptibility genes for asthma.   
 Based on this association and linkage surveys, it 
is logical to speculate that STAT2*C related genotype 
alterations could be primarily responsible for the ab-
errant immune response that characterizes asthma. 
STAT2*C related genotypes and allele variants might 
directly or indirectly influence the mRNA transla-
tions for innate immune events. The STAT2 genetic 
variation might result in the synonymous coding 
change. Therefore, it is plausible to suspect the inter-
vention, modification, determination or involvement 
of these STAT2 genetic variations upon the expres-
sion or stability of STAT2 as well as the following 
pathogenesis of asthma.   
 In this survey, we observed the non-association 
between STAT2 genotypes with FEV1 or FEV1/FVC, 
which suggested its roles upon asthma susceptibility 
rather than severities. Furthermore, there are also 
predictive values about its effects upon protein se-
quence. It suggested some STAT2 polymorphisms, 
might be associated with asthma risk as well as play-
ing potential candidate genetic markers in predicting 
the susceptibility of asthma. There is biological plau-
sibility for an association between the STAT2 poly-
morphisms in the exon or promoter regions and 
asthma risk. Our study should permit a more precise 
evaluation of the risks associated with individual 
susceptibility genes and a better insight into asthma 
pathogenesis. These polymorphisms might have po-
tential influences upon the expression of these repair 
proteins. However, the real roles and relationships of 
these genetic traits upon asthma remain complex to 
be clarified, especially concerning the effects of 
smoking or life styles additions.   
  In this survey, we also observed the 
non-correlations of asthma with the TLR4 and CD40 
polymorphisms. This  intervening sequence  located 
on mRNA-untranslated region might not influence 
the amino acid coding, mRNA production, genetic 
expression and illness susceptibilities. These findings 
suggested some genetic variations within the TLR4 
and CD40 might not be associated with the genetic 
presentation such as transcription and translations as 
well as asthma phenotypes and susceptibilities. In 
addition, the additional effects among TLR4 and 
CD40 halotypes might not be associated with the 
susceptibility and contribution for asthma. To the 
best of our knowledge, this is among the first few 
study to address the issue of an interaction between 
genetic variations of STAT2, TLR4 and CD40 and 
asthma risk.   
Taken together, STAT2*C genotype and allele 
might be correlated with asthma development and 
pathogenesis. In contrast, TLR4 and CD40 polymor-
phisms as well as the additional effects of their halo-
types were not associated with the different suscepti-
bility and contribution for asthma. These findings 
highlighted the values and potentials of the 
STAT2-realted genes upon the future surveys of 
asthma. STAT2 rs2066807 polymorphisms might be-
come potential markers for the prediction of asthma 
susceptibility. It also provides a valuable insight into 
the pathogenesis of asthma. Additional in-vitro or 
in-vivo researches are requested, including functional 
studies correlating genotype and phenotype for spe-
cific STAT2 alleles within endothelium tissues for Int. J. Biol. Sci. 2009, 5 
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airway. After the clarification of these issues, some 
STAT2 genetic variations might become useful mark-
ers to predict the future development of novel thera-
pies for asthma as well as the modulating or interfer-
ing factors of related pathogeneses.   
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